Navigation Links
Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
Date:7/30/2012

  • Sensitivity was reported at 94%
  • Performance for Early-Stage Ovarian Cancer (I and II)

    • Sensitivity was reported at 91%

    OVA1 as a Risk Stratification Test (OVA1 score versus cutoff, independent of physician assessment)

    • Sensitivity was reported at 92% overall:
      • 91% for early-stage disease
      • 94% for pre-menopausal patients
      • 91% for stage I and II in pre-menopausal women with a specificity of 61%

    "The data are a significant validation of the clinical trial from 2009, and these exciting new results, along with previous clinical data, support the continued efforts to expand our ovarian cancer franchise and create a new approach to treating this deadly disease," said Gail S. Page, CEO of Vermillion. "Ovarian cancer is an area of medicine where there continues to be a significant need for novel approaches. A key goal of the study was to investigate the challenging pre-menopausal setting, where benign cysts have a high incidence and early-stage cancer often goes undetected. OVA1 showed outstanding performance in this population, which clearly addresses an unmet need for physicians and patients alike."

    "OVA1 sensitivity and negative predictive value in the OVA500 study met or exceeded the levels reported in the pivotal trial, and confirmed the ability of OVA1 to detect a broad range of ovarian cancer subtypes," said Page. "Detection of a broad range of cancer subtypes is essential in triage, since it directly increases overall sensitivity and decreases the likelihood of finding a malignancy in patients with a low-risk assessment."

    Further details from the study have been submitted for peer-reviewed publication and presentation. Vermillion plans to utilize important findings like these as a tool to continue driving adoption and reimbursement of OVA1.

    This latest
    '/>"/>

    SOURCE Vermillion, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
    2. Vermillion Announces CEO Succession Plan
    3. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
    4. Insmed Announces Planned Departure Of Chief Financial Officer
    5. Absorption Systems announces novel test platform for interactions with the BCRP transporter
    6. Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
    7. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
    8. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
    9. Gentris Corporation Announces Collaboration to Study Blood Stability
    10. RoundTable Healthcare Partners Announces Sale of Aspen Surgical Products Holding, Inc. to Hill-Rom Holdings, Inc.
    11. Biomet Announces Pricing of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
    (Date:9/17/2014)... 17 2014 IBM (NYSE: IBM ) ... IBM technical computing and storage technology to accelerate ... These services deliver critically important information to help ... unique cancer, which could lead to better health ... in general. Today, optimal cancer care ...
    (Date:9/17/2014)... , September 17, 2014 ... to congratulate Biocartis commitment in shipping its first ... long-time investor in Biocartis as part of Debiopharm ... fully automated, real-time PCR based molecular diagnostics system, ... access to clinical molecular diagnostic information, anywhere and ...
    Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
    ... - NanoViricides,Inc. (Pink Sheets: NNVC) discussed today the ... presented along with the,successful BSL3 in vitro studies ... Annual Symposium of the Pan American Society for ... (Pan American Society,for Clinical Virology (PASCV): Clinical Virology ...
    ... and Symptom Severity; New,Resources for Patients, Parents, WASHINGTON, ... today by the National Consumers League shows that ... days. Four in,ten asthma sufferers understand asthma medication ... recent the diagnosis, the less,knowledgeable adult patients tend ...
    Cached Medicine Technology:Global Rabies Treatment May be Possible with NanoViricides Drugs 2New Survey Finds Troubling Data on American Asthma Sufferers 2New Survey Finds Troubling Data on American Asthma Sufferers 3New Survey Finds Troubling Data on American Asthma Sufferers 4New Survey Finds Troubling Data on American Asthma Sufferers 5New Survey Finds Troubling Data on American Asthma Sufferers 6
    (Date:9/17/2014)... York (PRWEB) September 17, 2014 The ... increase in worth due to the key driving factors ... advancements. An expected CAGR of 8.2 % puts the ... $730.2 million in 2018, as stated in a Transparency ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2012 ...
    (Date:9/17/2014)... news release is available in Spanish . ... affect more than half of the population in our ... one of which affects liver function. Fat accumulates in ... causes inflammation, fibrosis and finally, cirrhosis. To date, the ... hepatic biopsy. Imaging techniques such as abdominal ecography detect ...
    (Date:9/17/2014)... of America (GSA) invites all journalists to attend ... country,s largest interdisciplinary conference in the field of aging ... Media representatives may register free of charge. , An ... gathering at the Walter E. Washington Convention Center and ... "Making Connections: From Cells to Societies" and the program ...
    (Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 Neon Sport ... part in the fitness industry’s most anticipated event, Joe ... NV. Two fans will each take home a Neon ... Neon Sport supplements and gear. Fitmark will hold entries ... Olympia Expo, September 19-20th. , “There’s nothing more ...
    Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
    ... ... Pricing Discount! , ... UK (PRWEB) May 12, 2010 -- Citywide Cleaning Services - a division of Citywide Ventures ... 10% pricing discount on any new cleaning contracts. Also, the Company announced that it will ...
    ... pattern that predicts the likelihood of relapse in patients ... leukemia has been discovered. Researchers publishing in the open ... consistent pattern in five genes that has the potential ... from more aggressive treatment when first diagnosed with T-cell ...
    ... ... features allow even more companies to save money through better contract management by reduciing ... ... -- Network Contract Solutions has released new features allowing holding companies to take advantage ...
    ... allergy even exist, researchers find , TUESDAY, May ... information about the prevalence, diagnosis and treatment of food ... studies. , The articles looked at allergies to cow,s ... which account for more than 50 percent of all ...
    ... Center announced today that it has received a US$100,000 ... Gates Foundation. The grant will support an innovative ... assistant professor in the Department of Microbiology and Immunology, ... Immune Intervention." Joshi,s project is one of 78 ...
    ... goal of a secure nationwide health information network (NHIN), a ... evaluating the costs, effort and value of what is sometimes ... which appears in the May/June 2010 issue of Journal ... the initial assessment of that framework by health information exchange ...
    Cached Medicine News:Health News:Cleaning Service Pricing Discount 2Health News:Genetic pattern that predicts leukemia relapse discovered 2Health News:Network Contract Solutions Adds Holding Company Features to Extend Market Reach and Client Base 2Health News:Few High-Quality Studies on Food Allergies, Say Reviewers 2Health News:OUHSC receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2
    QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
    For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
    For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
    For the qualitative detection of luteinising Hormone (LH) in urine specimens...
    Medicine Products: